Gebasaxturev

2024 dermatology studies advanced skin health understanding and patient care, highlighting treatments like ligelizumab for urticaria, ACE2 as a COVID-19 biomarker, and JNJ-77242113 for psoriasis. AI's role in dermatology and ethnic differences in vulvar dermatoses were also explored.

DelveInsight's 'Melanoma Pipeline Insight 2024' covers 150+ companies and 170+ pipeline drugs, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, and BioNTech SE. Key therapies like Amtagvi (Iovance Biotherapeutics) received FDA fast-track approval in 2024 for metastatic melanoma. Neoadjuvant immunotherapy became standard care for stage III melanoma after ESMO 2024 updates. The report assesses therapies by product type, stage, route of administration, and molecule type, highlighting active and inactive pipeline products.